Does switching from coated colchicine to compressed colchicine improves treatment response in patients with familial Mediterranean fever?

IF 1.5 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Croatian Medical Journal Pub Date : 2023-10-31

Nimet Öner, Elif Çelikel, Zahide Ekici Tekin, Vildan Güngörer, Tuba Kurt, Müge Sezer, Nilüfer Tekgöz, Cüneyt Karagöl, Serkan Coşkun, Melike Mehveş Kaplan, Merve Cansu Polat, Banu Çelikel Acar

{"title":"Does switching from coated colchicine to compressed colchicine improves treatment response in patients with familial Mediterranean fever?","authors":"Nimet Öner, Elif Çelikel, Zahide Ekici Tekin, Vildan Güngörer, Tuba Kurt, Müge Sezer, Nilüfer Tekgöz, Cüneyt Karagöl, Serkan Coşkun, Melike Mehveş Kaplan, Merve Cansu Polat, Banu Çelikel Acar","doi":"","DOIUrl":null,"url":null,"abstract":"Aim: To evaluate the treatment response to compressed colchicine tablets in familial Mediterranean fever (FMF) patients with resistance or intolerance to coated colchicine. The secondary aim was to determine the demographic and clinical characteristics of responders to compressed colchicine.Methods: We retrospectively reviewed the medical records of 1574 pediatric patients with FMF treated at Ankara Bilkent City Hospital. Sixty-one patients did not respond to coated colchicine and were switched to compressed colchicine. In these patients, the number of attacks and the International Severity Score for FMF (ISSF) during the 6 months before and 3, 6, 9, 12, and 24 months after switching from coated colchicine to compressed colchicine were recorded.Results: Twelve of 61 patients (19.7%) who were switched to compressed colchicine due to intolerance responded to treatment. Of the 49/61 patients (80.3%) who were switched due to uncontrolled attacks and persistent subclinical inflammation, 25 responded to treatment. The frequency of attacks and ISSF decreased after switching. At the end of the two-year follow-up, 42 patients responded to compressed colchicine, and 19 patients received compressed colchicine plus interleukin-1-targeting drugs.Conclusions: Compressed colchicine was shown to be a useful treatment option before initiating biological agents in non-responders to coated colchicine, especially those with side effects.","PeriodicalId":10796,"journal":{"name":"Croatian Medical Journal","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668039/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Croatian Medical Journal","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To evaluate the treatment response to compressed colchicine tablets in familial Mediterranean fever (FMF) patients with resistance or intolerance to coated colchicine. The secondary aim was to determine the demographic and clinical characteristics of responders to compressed colchicine.

Methods: We retrospectively reviewed the medical records of 1574 pediatric patients with FMF treated at Ankara Bilkent City Hospital. Sixty-one patients did not respond to coated colchicine and were switched to compressed colchicine. In these patients, the number of attacks and the International Severity Score for FMF (ISSF) during the 6 months before and 3, 6, 9, 12, and 24 months after switching from coated colchicine to compressed colchicine were recorded.

Results: Twelve of 61 patients (19.7%) who were switched to compressed colchicine due to intolerance responded to treatment. Of the 49/61 patients (80.3%) who were switched due to uncontrolled attacks and persistent subclinical inflammation, 25 responded to treatment. The frequency of attacks and ISSF decreased after switching. At the end of the two-year follow-up, 42 patients responded to compressed colchicine, and 19 patients received compressed colchicine plus interleukin-1-targeting drugs.

Conclusions: Compressed colchicine was shown to be a useful treatment option before initiating biological agents in non-responders to coated colchicine, especially those with side effects.

本刊更多论文

从包被秋水仙碱改为压缩秋水仙碱是否能改善家族性地中海热患者的治疗反应？

目的：评价对包被秋水仙碱耐药或不耐受的家族性地中海热（FMF）患者对压缩秋水仙碱片的治疗效果。次要目的是确定压缩秋水仙碱反应者的人口统计学和临床特征。方法：我们回顾性分析了在安卡拉比尔肯特市医院接受治疗的1574例FMF患儿的医疗记录。61名患者对包衣秋水仙碱没有反应，改为使用压缩秋水仙碱。在这些患者中，记录了从包衣秋水仙碱转为压缩秋水仙碱前6个月以及转为包衣秋水仙素后3、6、9、12和24个月的发作次数和国际严重程度评分（ISSF）。结果：61例因不耐受而改用秋水仙碱的患者中，12例（19.7%）对治疗有反应。在因不受控制的发作和持续的亚临床炎症而转院的49/61名患者中（80.3%），有25名对治疗有反应。切换后，攻击频率和ISSF降低。在两年随访结束时，42名患者对秋水仙碱有反应，19名患者接受了秋水仙碱加白细胞介素-靶向药物治疗。结论：在对包被秋水仙碱无反应的患者，尤其是有副作用的患者，使用生物制剂之前，压缩秋水仙碱被证明是一种有用的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Croatian Medical Journal 医学-医学：内科

CiteScore

3.00

自引率

5.30%

发文量

105

审稿时长

6-12 weeks

期刊介绍： Croatian Medical Journal (CMJ) is an international peer reviewed journal open to scientists from all fields of biomedicine and health related research. Although CMJ welcomes all contributions that increase and expand on medical knowledge, the two areas are of the special interest: topics globally relevant for biomedicine and health and medicine in developing and emerging countries.